Skip to main content

Emicizumab Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Nov 2, 2022.

Emicizumab is also known as: Hemlibra

Emicizumab Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: Not assigned.

Risk Summary: No data exist to inform a drug-associated risk of major birth defects and miscarriage.

Comments: Women of childbearing potential should use contraception while receiving this drug.

Animal studies have not been reported. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Emicizumab Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Product Information. Hemlibra (emicizumab). Genentech. 2017.

References for breastfeeding information

  1. Product Information. Hemlibra (emicizumab). Genentech. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.